Safety and tolerability of COMT inhibitors

Neurology

Volumn 62, Issue 1 SUPPL. 1, 2004, Pages

  Brooks, David J ^a,b   Koller, ^c   Olanow, ^c   Hauser, ^c   Reinikainen, ^c   Poewe, ^c   Hubble, ^c   Stocchi, ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMILORIDE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; APOMORPHINE; ATORVASTATIN; BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CELECOXIB; DONEPEZIL; DOSULEPIN; DOXEPIN; ENTACAPONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ISOPRENALINE; LEVODOPA; LIVER ENZYME; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; NORADRENALIN; PERINDOPRIL; PLACEBO; ROFECOXIB; SELEGILINE; TOLCAPONE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ABDOMINAL PAIN; BILIARY TRACT DISEASE; CHOLESTASIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; HALLUCINATION; HEPATITIS; HUMAN; INSOMNIA; JAUNDICE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; URINE COLOR; VOMITING; WITHDRAWAL SYNDROME;

EID: 0347092049     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.62.1_suppl_1.s39     Document Type: Review

References (34)

1. Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyl transferase. Gen Pharmacol 1994;25:813-824.
2. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyl transferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
3. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-1250.
4. Stocchi F, De Pandis MF, Vacca L, Valente M, Brusa L, Ruggieri S. Entacapone efficacy in Parkinson's disease. Mov Disord 2000;15(suppl 3):S127. Abstract.
5. Jorga K, Banken L, Fotteler B, Snell P, Steimer JL. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. Clin Pharmacol Ther 2000;67:610-620.
6. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, and the NOMECOMT Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-1314.
7. Gordin A, Kaakkola S, Teravainen K. Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol 2003;91:237-250.
8. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR, Rubbici-Brandt L. Tolcapone and fulminant hepatitis. Lancet 1998;352:958.
9. Colosimo C. The rise and fall of tolcapone. J Neurol 1999;246:880-882.
10. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
11. Poewe WH, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M, and the CELOMEN Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria. Acta Neurol Scand 2002;105:245-255.
12. Myllyla VV, Kultalahti E-R, Haapaniemi H, Leinonen M, and the FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:53-60.
13. Brooks DJ, Sagar H, and the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, doubleblind six-month study. J Neurol Neurosurg Psychiatry 2003;74:1064-1072.
14. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, and the NOMESAFE Study Group. The tolerability and efficacy of entacapone over three years in patients with Parkinson's disease. Eur Neurol 2003;10:137-146.
15. Poewe W, Deuschl G, Kultalahti, E-R, Reinikainen K, Leinonen M, and the CELOSAFE Study Group. Entacapone is safe in long-term use in patient's with Parkinson's disease. An Austrian-German open two year safety and one year efficacy study. Eur J Neurol 2003;10(suppl 1):241. Abstract.
16. Waters C, Heikinen H, Holopainen A, Leinonen M, Gordin A, and the SEESAFE Study Group. Entacapone is safe in long-term use in patients with Parkinson's disease. A North American open three year safety and one year efficacy study. Eur J Neurol 2003;10(suppl 1):241. Abstract.
17. Haapaniemi H, Reinikainen K, Leinonen M, et al. Tolerability and safety of entacapone in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2001;7(suppl 1):S57. Abstract.
18. Reinikainen K, Leinonen M, Isojarvi J, et al. Predicting the need for levodopa dose reduction after entacapone initiation in PD patients with end-of-dose wearing-off (EODWO). Mov Disord 2002;17(suppl 5):P111. Abstract.
19. Orion Pharma (UK) Ltd. Comtess. Summary of product characteristics. September, 2002.
20. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, doubleblind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-87.
21. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
22. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the " wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
23. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997;49:665-671.
24. Illi A, Sundberg S, Koulu M, Scheinin M, Heinavaara S, Gordin A. COMT inhibition by entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994;32:582-588.
25. Orion Pharma. Liver safety review of entacapone. Data on file, December, 2002.
26. Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ. Entacaponeinduced hepatotoxicity and hepatic dysfunction. Mov Disord 2002;17:1362-1365.
27. Beck S, Hubble J, Reinikainen K. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 2002;17:1397-1399. Letter.
28. Wikberg T, Vuorela A, Ottoila P, Taskinen J. Identification of major metabolites of the catechol-O-methyl transferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993;21:81-92.
29. Jorga K, Fotteler B, Heizmann P, Gasser R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyl transferase. Br J Clin Pharmacol 1999;48:513-520.
30. Nissinen E, Kaheinen P, Penttila KE, Kaivola J, Linden I-B. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 1997;340:287-294.
31. Lyytinen J, Kaakkola S, Gordin A, Kultalahti E-R, Teravainen H. Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study. Parkinsonism Relat Disord 2000;6:215-222.
32. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996;59:450-457.
33. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 1996;51:273-276.
34. Reinikainen K, Karonen T, Haapaniemi H. No indication for interactions between entacapone and anti-depressants. Parkinsonism Relat Disord 2001;7(supp 1):S67. Abstract.